MyFinsight
Home
Blog
About
Increase in other assets
-$82,387K
Increase in inventory
-$39,911K
Decrease in
manufacturing-related deposits and...
-$25,792K
Stock-based compensation
$24,472K
(decrease) increase in
accrued expenses
$22,695K
Decrease (increase) in
accounts receivable
-$17,993K
Non-cash inventory
write-downs for...
$11,599K
Depreciation and
amortization
$10,409K
Non-cash interest
expense
$9,394K
(decrease) increase in
lease liabilities and...
$6,084K
Reduction in the carrying
amounts of the right of...
$3,212K
Loss on strategic
investments
-$448K
Net cash used in
operating activities
$197,070K
Canceled cashflow
$57,326K
Decrease in cash, cash
equivalents and restricted...
$103,698K
Canceled cashflow
$93,372K
Decrease in deferred
revenue
-$32,127K
Decrease in accounts
payable
-$19,394K
Net income (loss)
-$4,890K
Accretion of investment
discount, net
-$905K
Other
$10K
something is missing
$170,197K
Maturity and sales of
available-for-sale securities
$88,031K
Net cash provided by
investing activities
-$93,372K
Canceled cashflow
$258,228K
Purchase of investments
$351,045K
Purchase of property and
equipment
$555K
Back
Back
Cash Flow
logo (1) copy-svg
Sarepta Therapeutics, Inc. (SRPT)
logo (1) copy-svg
source: myfinsight.com
Sarepta Therapeutics, Inc. (SRPT)